Despite these caveats, RECs retain predictive capacity by gene expression (Regen71) and immunophenotype (CD74/CD68), suggesting RECs play a significant role in a large fraction of AML cases but may be increasingly powerful should additional stratification of AML patients be applied. Here, CD68 is linked to acute myeloid leukemia.